首页> 美国卫生研究院文献>Drugs in Context >Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department
【2h】

Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department

机译:过敏性鼻结膜炎和荨麻疹中的比拉司汀:根据医疗信息部门收到的询问做出治疗决定的实用方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBilastine is a safe and effective commonly prescribed non-sedating H1-antihistamine approved for symptomatic treatment in patients with allergic disorders such as rhinoconjunctivitis and urticaria. It was evaluated in many patients throughout the clinical development required for its approval, but clinical trials generally exclude many patients who will benefit in everyday clinical practice (especially those with coexisting diseases and/or being treated with concomitant drugs). Following its introduction into clinical practice, the Medical Information Specialists at Faes Farma have received many practical queries regarding the optimal use of bilastine in different circumstances.
机译:背景技术Bilastine是一种安全有效的通常开处方的非镇静性H1抗组胺药,已被批准用于过敏性疾病(如鼻结膜炎和荨麻疹)的对症治疗。在其批准所需的整个临床开发过程中,对许多患者进行了评估,但临床试验通常排除了许多将受益于日常临床实践的患者(尤其是那些患有并存疾病和/或接受伴随药物治疗的患者)。在将其引入临床实践之后,Faes Farma的医学信息专家已经收到了许多有关在不同情况下最佳使用比拉汀的实际问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号